VAN ANDEL INSTITUTE®

FOUNDED BY JAY AND BETTY VAN ANDEL

IBC Meeting Minutes
Date: April 15, 2026
Location: Conf. Room 2101/2102

Voting Members Present (8):
Michael Henderson, Ph.D. (Chair)
Glen Alberts, B.S.
Pamela Bartlett, B.S.
Craig Bickel, M.Div.
Nicholas Burton, Ph.D.
Matthew Donahue, MBA
Angie Jason (non-voting)
Rachael Sheridan, Ph.D.
Jennifer Steiner, Ph.D.

Voting Members Excused (3):
Scott Bechaz, ILAM, RLATg
Lauren Miedema, B.S., MPH
Sam Pinto, B.S. (Vice Chair)

Christy Goss (guest)

Call to Order
Michael Henderson called the meeting to order at 9:32 a.m.

Meeting Minutes – Minutes from the IBC meeting on 01/21/26 were approved unanimously.
Vote: (8 Total) 8 Approve 0 Disapprove 0 Abstain 0 Recuse

New Business

- Discussion took place regarding new EHS-led changes to the IBC form in Tick@Lab.

Protocol Reviews

A. Reference #26-0026 – Initial – Clifford Cho, Ph.D.
"Sensitizing cancer to immunotherapy using histotripsy focused ultrasound ablation"
Primary Reviewer: Rachael Sheridan

The purpose of this protocol is to model *in vitro* using histotripsy to partially ablate solid tumors *in vivo*. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. General Information – The investigator was asked to modify the public facing summary.
2. Training – The investigator was asked to ensure training is completed.
3. Project Category – The investigator was asked to correct the type, attach pdfs of vector maps and place lentiviral transduction under host vector system.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2
Containment Level: BSL2

Location Assessment: Level 4, Phase 1 - Tissue Culture Rm 4131

Action: Modifications to secure approval.

Vote: (8 Total) 8 Approve 0 Disapprove 0 Abstain 0 Recuse

B. Reference #26-0023 – Initial – Yvonne Fondufe-Mittendorf, Ph.D.
"Nucleosome dynamic changes in aggressive breast cancer and immune evasion in response to growth and environmental cues"
Primary Reviewer: Glen Alberts

The purpose of this protocol is to study how changes in DNA packaging in aggressive breast cancers help tumors hide from the immune system and resist being destroyed. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. General Information – The investigator was asked to add specific grant information for congruence purposes.
2. Personnel – The investigator was asked to verify personnel list is complete.
3. Project Categories – The investigator was asked to uncheck box for select agent.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2
Containment Level: BSL2

Location Assessment: 5024W, 5113W, 5121W, 5119W, and 5125W

Action: Modifications to secure approval.

Vote: (8 Total) 8 Approve 0 Disapprove 0 Abstain 0 Recuse

C. Reference #26-0019 – 3 Year Re-Write – Josh Jang, Ph.D.
"Lentiviral Systems for Cancer Cell Lines"
Primary Reviewer: Jennifer Steiner

The purpose of this protocol is to use replication-incompetent lentiviral vectors to deliver siRNA and CRISPR-Cas9-based gene regulation tools into cultured mammalian cancer cells to modulate expression of specific genes and epigenetic regulators to study their roles in cancer cell behaviour and response to treatment. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. Project Categories – The investigator was asked to update the plasmid attachments.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2
Containment Level: BSL2

Location Assessment: Phase 1, Level 4, Room 4120

Action: Modifications to secure approval.

Vote: (8 Total) 8 Approve 0 Disapprove 0 Abstain 0 Recuse

D. Reference #26-0018 – 3 Year Re-Write – Nick Burton, Ph.D.
"Identifying the genes in bacteria that regulate C. elegans insulin signaling"
Primary Reviewer: Nick Burton

The purpose of this protocol is to study how microbiome bacteria can impact animal metabolism. We collect common commensal bacteria from the environment and screen them for rare bacteria that can "cure" models of human metabolic diseases in the model animal Caenorhabditis elegans. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

Nick Burton was recused.

1. General Information – The investigator was asked to modify the public facing summary.
2. Project Categories – The investigator was asked to attach Tn5 details.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 1
Containment Level: BSL1

Location Assessment: Burton Lab space in Floor 4 of Phase 2 lab space.

Action: Modifications to secure approval.

Vote: (8 Total) 7 Approve 0 Disapprove 0 Abstain 1 Recuse

Meeting was adjourned at 9:53 am